SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
February 23, 2021
(Exact Name of Registrant as Specified in Charter)
|(State or Other Jurisdiction|
400 Technology Square, 4th Floor
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including area code: (617) 229-5872
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common stock, $0.0001 par value||EPZM||Nasdaq Global Select Market|
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
This Current Report on Form 8-K/A amends and supplements the Current Report on Form 8-K of Epizyme, Inc., a Delaware corporation (the “Company”), originally furnished to the Securities and Exchange Commission on February 23, 2021 (the “Initial Form 8-K”). The sole purpose for filing this Form 8-K/A is to update certain information contained in one of the sub-headings in the press release that was furnished as Exhibit 99.1 to the Initial Form 8-K.
Results of Operations and Financial Condition
The Initial Form 8-K included, as Exhibit 99.1, the press release previously issued on February 23, 2021, which reported the financial results of the Company for the quarter and year ended December 31, 2020 and some business updates.
The Company has issued a corrected version of the press release, clarifying that only the Phase 1b portion (and not the Phase 2 portion) of the Company’s ongoing Phase 1b/2 clinical trial in castration-resistant prostate cancer is fully enrolled. The full text of the corrected press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K/A and is incorporated herein by reference.
The information provided under Item 2.02 of this Form 8-K/A (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
|99.1||Corrected press release issued by the Company on February 23, 2021*|
|104||Cover Page Interactive Date File (embedded within Inline XBRL document)|
The exhibit shall be deemed to be furnished, and not filed.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: February 23, 2021||By:|
/s/ John Weidenbruch